KR20230074733A - Myc 패밀리 원종양유전자 단백질의 조정제 - Google Patents
Myc 패밀리 원종양유전자 단백질의 조정제 Download PDFInfo
- Publication number
- KR20230074733A KR20230074733A KR1020237010219A KR20237010219A KR20230074733A KR 20230074733 A KR20230074733 A KR 20230074733A KR 1020237010219 A KR1020237010219 A KR 1020237010219A KR 20237010219 A KR20237010219 A KR 20237010219A KR 20230074733 A KR20230074733 A KR 20230074733A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- heterocyclyl
- methyl
- group
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070762P | 2020-08-26 | 2020-08-26 | |
| US202063070753P | 2020-08-26 | 2020-08-26 | |
| US63/070,762 | 2020-08-26 | ||
| US63/070,753 | 2020-08-26 | ||
| PCT/US2021/047489 WO2022046861A1 (en) | 2020-08-26 | 2021-08-25 | Modulators of myc family proto-oncogene protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230074733A true KR20230074733A (ko) | 2023-05-31 |
Family
ID=77775028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237010219A Withdrawn KR20230074733A (ko) | 2020-08-26 | 2021-08-25 | Myc 패밀리 원종양유전자 단백질의 조정제 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230322722A1 (https=) |
| EP (1) | EP4204411A1 (https=) |
| JP (1) | JP2023543670A (https=) |
| KR (1) | KR20230074733A (https=) |
| AU (1) | AU2021333760A1 (https=) |
| BR (1) | BR112023003517A2 (https=) |
| CA (1) | CA3190539A1 (https=) |
| IL (1) | IL300906A (https=) |
| MX (1) | MX2023002378A (https=) |
| TW (1) | TW202227411A (https=) |
| WO (1) | WO2022046861A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202325272A (zh) * | 2021-10-29 | 2023-07-01 | 日商田邊三菱製藥股份有限公司 | 新穎之螺環化合物 |
| US20250177393A1 (en) * | 2022-02-25 | 2025-06-05 | Nalo Therapeutics | Modulators of myc family proto-oncogene protein |
| WO2025043063A1 (en) * | 2023-08-24 | 2025-02-27 | Nalo Therapeutics, Inc. | Modulators of myc family proto-oncogene protein |
| WO2025043065A1 (en) * | 2023-08-24 | 2025-02-27 | Nalo Therapeutics, Inc. | Modulators of myc family proto-oncogene protein |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003286711A1 (en) * | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| ATE519759T1 (de) * | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
| US20070179125A1 (en) * | 2005-11-16 | 2007-08-02 | Damien Fraysse | Aminopyrimidines useful as kinase inhibitors |
| US8101621B2 (en) * | 2006-04-27 | 2012-01-24 | Msd K.K. | Aminopyridine derivatives having aurora a selective inhibitory action |
| WO2010144522A1 (en) * | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
| CN103781779B (zh) * | 2011-09-05 | 2016-06-08 | 浙江海正药业股份有限公司 | 具有蛋白激酶抑制活性的4-取代-(3-取代-1h-吡唑-5-氨基)-嘧啶衍生物及其用途 |
| SG11202001706RA (en) * | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| US11584737B2 (en) * | 2018-03-29 | 2023-02-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2020108516A1 (zh) * | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| CN113710663A (zh) * | 2019-02-19 | 2021-11-26 | 纳罗医疗公司 | Myc家族原癌基因蛋白的调节剂 |
-
2021
- 2021-08-25 CA CA3190539A patent/CA3190539A1/en active Pending
- 2021-08-25 KR KR1020237010219A patent/KR20230074733A/ko not_active Withdrawn
- 2021-08-25 JP JP2023513890A patent/JP2023543670A/ja active Pending
- 2021-08-25 EP EP21770396.6A patent/EP4204411A1/en not_active Withdrawn
- 2021-08-25 BR BR112023003517A patent/BR112023003517A2/pt not_active Application Discontinuation
- 2021-08-25 MX MX2023002378A patent/MX2023002378A/es unknown
- 2021-08-25 IL IL300906A patent/IL300906A/en unknown
- 2021-08-25 WO PCT/US2021/047489 patent/WO2022046861A1/en not_active Ceased
- 2021-08-25 AU AU2021333760A patent/AU2021333760A1/en not_active Abandoned
- 2021-08-25 US US18/023,298 patent/US20230322722A1/en active Pending
- 2021-08-26 TW TW110131640A patent/TW202227411A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023002378A (es) | 2023-05-22 |
| IL300906A (en) | 2023-04-01 |
| AU2021333760A1 (en) | 2023-04-06 |
| CA3190539A1 (en) | 2022-03-03 |
| BR112023003517A2 (pt) | 2023-05-09 |
| US20230322722A1 (en) | 2023-10-12 |
| WO2022046861A1 (en) | 2022-03-03 |
| JP2023543670A (ja) | 2023-10-18 |
| TW202227411A (zh) | 2022-07-16 |
| EP4204411A1 (en) | 2023-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12410193B2 (en) | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | |
| AU2020214404B2 (en) | Immunomodulators, compositions and methods thereof | |
| AU2020273302B2 (en) | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | |
| AU2015311805B2 (en) | Inhibitors of lysine specific demethylase-1 | |
| JP2024523657A (ja) | ホスファターゼ分解剤の合成及び応用 | |
| US9856262B2 (en) | Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors | |
| KR20230074733A (ko) | Myc 패밀리 원종양유전자 단백질의 조정제 | |
| US9187464B2 (en) | TRPV4 antagonists | |
| TW202102509A (zh) | 靶向prmt5之化合物 | |
| CN115003655A (zh) | 环烷基脲衍生物 | |
| AU2015276699B2 (en) | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor | |
| US11034696B2 (en) | Compounds for inhibiting LRRK2 kinase activity | |
| AU2005277638A1 (en) | Chemical compounds | |
| US20210369710A1 (en) | Modulators of myc family proto-oncogene protein | |
| US10961238B2 (en) | Modulators of hedgehog (Hh) signaling pathway | |
| WO2022076973A1 (en) | 7-azaindole compounds for inhibition of bcr-abl tyrosine kinases | |
| KR102682398B1 (ko) | 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도 | |
| CN117980297A (zh) | 作为egfr抑制剂的取代的氨基吡啶化合物 | |
| CN113164481A (zh) | 环烷-1,3-二胺衍生物 | |
| JP2024502106A (ja) | ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用 | |
| CN116981458A (zh) | 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物 | |
| CN116490499A (zh) | Myc家族原癌基因蛋白的调节剂 | |
| CA3172830A1 (en) | Potent and selective irreversible inhibitors of irak1 | |
| WO2025043065A1 (en) | Modulators of myc family proto-oncogene protein | |
| HK40063870A (en) | Modulators of myc family proto-oncogene protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PC1203 | Withdrawal of no request for examination |
St.27 status event code: N-1-6-B10-B12-nap-PC1203 |